NO332619B1 - Farmasoytisk kombinasjon for behandling av en kreftform som uttrykker HER2 - Google Patents
Farmasoytisk kombinasjon for behandling av en kreftform som uttrykker HER2 Download PDFInfo
- Publication number
- NO332619B1 NO332619B1 NO20014842A NO20014842A NO332619B1 NO 332619 B1 NO332619 B1 NO 332619B1 NO 20014842 A NO20014842 A NO 20014842A NO 20014842 A NO20014842 A NO 20014842A NO 332619 B1 NO332619 B1 NO 332619B1
- Authority
- NO
- Norway
- Prior art keywords
- docetaxel
- her2
- rhumab her2
- dose
- patients
- Prior art date
Links
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title claims abstract description 88
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title claims abstract description 87
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 32
- 201000011510 cancer Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims description 23
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 80
- 229960003668 docetaxel Drugs 0.000 claims abstract description 77
- 230000003442 weekly effect Effects 0.000 claims description 21
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 7
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102000052575 Proto-Oncogene Human genes 0.000 claims description 3
- 108700020978 Proto-Oncogene Proteins 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 230000004044 response Effects 0.000 description 34
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000001802 infusion Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003708 ampul Substances 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 229940063683 taxotere Drugs 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000009093 first-line therapy Methods 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 208000004235 neutropenia Diseases 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000002633 Febrile Neutropenia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009094 second-line therapy Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 150000004625 docetaxel anhydrous derivatives Chemical class 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12856499P | 1999-04-09 | 1999-04-09 | |
PCT/US2000/009247 WO2000061185A1 (en) | 1999-04-09 | 2000-04-07 | Docetaxel in combination with rhumab her2 for the treatment of cancers |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014842L NO20014842L (no) | 2001-10-04 |
NO20014842D0 NO20014842D0 (no) | 2001-10-04 |
NO332619B1 true NO332619B1 (no) | 2012-11-19 |
Family
ID=22435924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014842A NO332619B1 (no) | 1999-04-09 | 2001-10-04 | Farmasoytisk kombinasjon for behandling av en kreftform som uttrykker HER2 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6333348B1 (de) |
EP (1) | EP1169059B1 (de) |
JP (2) | JP2003512298A (de) |
KR (1) | KR100695383B1 (de) |
CN (1) | CN1191859C (de) |
AT (1) | ATE307608T1 (de) |
AU (1) | AU777661B2 (de) |
BR (1) | BR0009647A (de) |
CA (1) | CA2368369C (de) |
CZ (1) | CZ296373B6 (de) |
DE (1) | DE60023476T2 (de) |
DK (1) | DK1169059T3 (de) |
EA (1) | EA006097B1 (de) |
ES (1) | ES2248070T3 (de) |
HK (2) | HK1043313A1 (de) |
HU (1) | HU226672B1 (de) |
MX (1) | MXPA01010138A (de) |
NO (1) | NO332619B1 (de) |
NZ (1) | NZ515337A (de) |
TR (1) | TR200102845T2 (de) |
WO (1) | WO2000061185A1 (de) |
ZA (1) | ZA200107771B (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
AU2004202605B2 (en) | 1998-07-13 | 2007-10-25 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6818213B1 (en) * | 1998-07-13 | 2004-11-16 | Board Of Regents, The University Of Texas System | Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids |
IL140700A0 (en) * | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
DK1189634T3 (da) * | 1999-06-25 | 2007-06-25 | Genentech Inc | Behandling af prostatacancer med anti-ErbB2-antistoffer |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
GB9917012D0 (en) * | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
ES2330301T3 (es) * | 1999-08-27 | 2009-12-09 | Genentech, Inc. | Dosificaciones para tratamiento con anticuerpos anti-erbb2. |
NZ522444A (en) * | 2000-05-19 | 2004-09-24 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
AU2002232413A1 (en) * | 2000-11-21 | 2002-06-03 | Cell Pathways, Inc. | Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor |
DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
CN104274442A (zh) | 2001-02-19 | 2015-01-14 | 诺华股份有限公司 | 癌症的治疗 |
US7664543B2 (en) * | 2001-04-26 | 2010-02-16 | Analogic Corporation | CT scanner for and method of imaging a preselected portion of the lower abdomen region of a patient |
US7452539B2 (en) * | 2001-12-19 | 2008-11-18 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
GB0200657D0 (en) * | 2002-01-12 | 2002-02-27 | Antisoma Plc | Cancer treatment |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7247303B2 (en) * | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
KR20150021911A (ko) * | 2002-07-15 | 2015-03-03 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염 및 암을 치료하는데 있어서 이의 용도 |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
JP2006516117A (ja) * | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
EP3698807A1 (de) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixe dosierung von her-antikörpern |
JP2008530123A (ja) * | 2005-02-09 | 2008-08-07 | ジェネンテック・インコーポレーテッド | マトリックスメタロプロテアーゼアンタゴニストを用いたher2のシェディングの阻害 |
EP2399605A1 (de) | 2005-02-23 | 2011-12-28 | Genentech, Inc. | Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
CA2624086A1 (en) * | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
EP1913958B1 (de) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab |
FR2904782B1 (fr) * | 2006-08-11 | 2008-10-31 | Delta Proteomics Soc Par Actio | Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques |
JP2010520225A (ja) | 2007-03-02 | 2010-06-10 | ジェネンテック, インコーポレイテッド | 低her3発現に基づくher二量化インヒビターに対する応答を予測する方法 |
SI2171090T1 (sl) | 2007-06-08 | 2013-07-31 | Genentech, Inc. | Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2133433A1 (de) * | 2008-06-09 | 2009-12-16 | Centre Georges François Leclerc | Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
WO2010061269A2 (en) * | 2008-11-02 | 2010-06-03 | Optimata Ltd. | Improving cancer therapy by docetaxel and granulocyte colony-stimulating factor (g-csf) |
MD23Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare |
MD35Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare |
MD36Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare |
MD24Z (ro) * | 2008-12-02 | 2010-01-31 | Василе ЖОВМИР | Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
DK2536748T3 (da) | 2010-02-18 | 2014-10-13 | Genentech Inc | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft |
RS58784B1 (sr) | 2010-05-06 | 2019-06-28 | Milosavljevic Goran | Farmaceutske kompozicije niske toksičnosti koje sadrže diterpenska jedinjenja sa antineoplastičnim dejstvom |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2013025853A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
MX357759B (es) * | 2011-09-01 | 2018-07-24 | Vascular Biogenics Ltd | Formulaciones y formas de dosificacion de fosfolipidos oxidados. |
CN102321175B (zh) * | 2011-09-21 | 2013-08-07 | 天津胜发生物技术有限公司 | 针对乳腺癌Her2/new的纳米抗体或多肽 |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
CN104271761B (zh) | 2011-11-30 | 2017-03-15 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
EP2788500A1 (de) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identifizierung von non-respondern auf her2-inhibitoren |
SG11201406079TA (en) | 2012-03-27 | 2014-10-30 | Genentech Inc | Diagnosis and treatments relating to her3 inhibitors |
US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
CN103102414B (zh) * | 2013-02-04 | 2014-08-27 | 无锡傲锐东源生物科技有限公司 | 抗her2蛋白单克隆抗体及其用途 |
US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
CN109966499A (zh) * | 2019-04-25 | 2019-07-05 | 苏州大学 | 协同增效的抗乳腺癌转移药物组合物及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
-
2000
- 2000-04-06 US US09/544,176 patent/US6333348B1/en not_active Expired - Lifetime
- 2000-04-07 ES ES00923156T patent/ES2248070T3/es not_active Expired - Lifetime
- 2000-04-07 KR KR1020017012798A patent/KR100695383B1/ko not_active IP Right Cessation
- 2000-04-07 EA EA200101064A patent/EA006097B1/ru not_active IP Right Cessation
- 2000-04-07 CN CNB008060886A patent/CN1191859C/zh not_active Expired - Fee Related
- 2000-04-07 NZ NZ515337A patent/NZ515337A/en not_active IP Right Cessation
- 2000-04-07 TR TR2001/02845T patent/TR200102845T2/xx unknown
- 2000-04-07 HU HU0201459A patent/HU226672B1/hu not_active IP Right Cessation
- 2000-04-07 EP EP00923156A patent/EP1169059B1/de not_active Expired - Lifetime
- 2000-04-07 AT AT00923156T patent/ATE307608T1/de active
- 2000-04-07 JP JP2000610517A patent/JP2003512298A/ja active Pending
- 2000-04-07 DE DE60023476T patent/DE60023476T2/de not_active Expired - Lifetime
- 2000-04-07 CA CA2368369A patent/CA2368369C/en not_active Expired - Fee Related
- 2000-04-07 WO PCT/US2000/009247 patent/WO2000061185A1/en active IP Right Grant
- 2000-04-07 MX MXPA01010138A patent/MXPA01010138A/es active IP Right Grant
- 2000-04-07 AU AU43327/00A patent/AU777661B2/en not_active Ceased
- 2000-04-07 DK DK00923156T patent/DK1169059T3/da active
- 2000-04-07 CZ CZ20013614A patent/CZ296373B6/cs not_active IP Right Cessation
- 2000-04-07 BR BR0009647-4A patent/BR0009647A/pt not_active Application Discontinuation
-
2001
- 2001-09-20 ZA ZA200107771A patent/ZA200107771B/en unknown
- 2001-10-04 NO NO20014842A patent/NO332619B1/no not_active IP Right Cessation
-
2002
- 2002-07-02 HK HK02104971.3A patent/HK1043313A1/zh unknown
- 2002-10-17 HK HK02107549.9A patent/HK1046093B/zh not_active IP Right Cessation
-
2012
- 2012-02-21 JP JP2012035366A patent/JP2012136535A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO332619B1 (no) | Farmasoytisk kombinasjon for behandling av en kreftform som uttrykker HER2 | |
US11866500B2 (en) | Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers | |
CN110337450B (zh) | Her2阳性乳腺癌的辅助治疗 | |
US20160243124A1 (en) | Method for treating acute myeloid leukemia | |
US20030096823A1 (en) | Method for the treatment of cardiotoxicity induced by antitumor compounds | |
KR20110036604A (ko) | 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물 | |
US20150139936A1 (en) | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics | |
US20230201303A1 (en) | Methods for treating pancreatic cancer and other solid tumors | |
TW202322855A (zh) | 人類表皮生長因子第二型受體疫苗組成物以及套組 | |
NO20111286L (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
WO2021224381A1 (en) | Combination therapy for treating cancer | |
D'Orazio et al. | The Addition of Carboplatin to Trastuzumab/Paclitaxel Improves Efficacy in HER2-Overexpressing Metastatic Breast Cancer | |
Egerton | Ixabepilone Treatment Schedules in Advanced Breast Cancer | |
Greystoke et al. | combination with carboplatin given on day 1 alone in patients with advanced solid tumours | |
WO2004073719A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA |
|
MM1K | Lapsed by not paying the annual fees |